| Patents for A61P 1 - Drugs for disorders of the alimentary tract or the digestive system (125,798) |
|---|
| 01/02/2003 | EP1267895A1 Use of feracryl for the treatment of peptic/duodenal ulcer and/or cholera |
| 01/02/2003 | EP1267883A2 Bile secretion promoting composition containing a prostaglandin |
| 01/02/2003 | EP1267881A2 Use of analogues of superoxide dismutase for treating hepatocellular insufficiencies |
| 01/02/2003 | EP1267880A1 Low dose entecavir formulation and use |
| 01/02/2003 | EP1267875A1 Sigma receptor ligands and their medical uses |
| 01/02/2003 | EP1267857A1 Method of inhibiting the expression of inflammatory cytokines and chemokines |
| 01/02/2003 | EP1267846A1 Transdermal therapeutic system for the delivery of lerisetron |
| 01/02/2003 | EP1267837A1 Matrices containing nitric oxide donors and reducing agents and their use |
| 01/02/2003 | EP1267828A2 Pharmaceutical preparations |
| 01/02/2003 | EP1267826A1 Pharmaceutical composition for treatment of mucosal epithelial ulceration and/or erosion |
| 01/02/2003 | EP1149832B1 Benzamide derivatives and drugs containing the same |
| 01/02/2003 | EP1139755A4 Method for treatment of bacterial infections with once or twice-weekly administered rifalazil |
| 01/02/2003 | EP1073452B1 Use of deltorphin for treating cytokine mediated hepatic injury |
| 01/01/2003 | CN1388757A Bioavailable dosage form of isotretinoin |
| 01/01/2003 | CN1388126A 吡咯并三嗪和嘧啶化合物 Pyrrolo-triazine and pyrimidine compounds |
| 01/01/2003 | CN1388118A Substituted phenyl alkyl nitrogen monoxide synthase inhibitor and its prepn and use |
| 01/01/2003 | CN1387914A Hepatitis B vaccine with lactic acid-ethanediol copolymer as adjuvant |
| 01/01/2003 | CN1387913A Buccal tablet containing SOD |
| 01/01/2003 | CN1387909A Natural medicated health food with the functions of romoving toxic material to protect liver and relaxing the bowels to expel toxin |
| 01/01/2003 | CN1387908A Hepatosis treating medxcine |
| 01/01/2003 | CN1387907A Production process of wolfberry fruit capsule |
| 01/01/2003 | CN1387901A Medicine for treating enteron diseases |
| 01/01/2003 | CN1387897A Wind-fire toothache powder and its prepn |
| 01/01/2003 | CN1387894A Chinese herbal medicine for treating hepatitis A |
| 01/01/2003 | CN1387892A Medicine tablet for treating acute and chronic cholecytitis and cholelithiais and its prepn process |
| 01/01/2003 | CN1387891A Chinese medicine prepn for treating deficiency of spleen and stomach Yang type atrophic gastritis |
| 01/01/2003 | CN1387889A Chinese medicine prepn for treating deficiency of spleen and stomach Yin type atrophic gastritis |
| 01/01/2003 | CN1387875A Recipe and prepn process of spleen and kidney invigorating medicine |
| 01/01/2003 | CN1387869A Gastropathy treating medicine |
| 01/01/2003 | CN1387864A Medicine for treating stomatocase and throat ache and its prepn |
| 01/01/2003 | CN1387852A Compound stomatocase-treating capsule |
| 01/01/2003 | CN1387850A 复方东莨菪碱 Compound scopolamine |
| 01/01/2003 | CN1097461C Paste for treating child diarrhoea |
| 01/01/2003 | CN1097456C Method for manufacturing troche for eliminating gastrointestinal vesicle and its application |
| 12/31/2002 | US6500936 Glycerol culture of actinomyces |
| 12/31/2002 | US6500864 Disulfide derivatives useful for treating allergic diseases |
| 12/31/2002 | US6500863 Interleukin binding inhibitors such as n-(2-hydroxyl-3-amino sulfonyl-4-chlorophenyl)-n'-(2-bromophenyl)urea, used for prophylaxis of chemokine mediated diseases |
| 12/31/2002 | US6500856 For therapy of inflammatory diseases and other diseases involving elevated levels of cytokines and proinflammatory mediators |
| 12/31/2002 | US6500839 CRF receptor antagonists and methods relating thereto |
| 12/31/2002 | US6500835 Preventive or therapeutic drugs for fibrosis containing chymase inhibitors as the active ingredient |
| 12/31/2002 | US6500822 Benzocycloalkylenylamine derivatives as muscarinic receptor antagonists |
| 12/31/2002 | US6500818 Naphthalenecarboxamides as tachykinin receptor antagonists |
| 12/31/2002 | US6500641 Expression vector wherein said expression vector comprises a polynucleotide promoter sequence, a polynucleotide encoding a signal sequence, a polynucleotide encoding an antigen protein or peptide, a polynucleotide encoding a cell binding element, |
| 12/31/2002 | US6500472 For enriching foods or beverages, anemia treatment |
| 12/31/2002 | US6500467 Bacterial strain, processed plant extracts, compositions containing same, processes for their preparation and their therapeutic and industrial applications |
| 12/31/2002 | US6500463 Mixing plasticizable matrix material, liquid plasticizer, encapsulant, non-plasticizable non-gelatinized starch, and component for controlling rate of release of encapsulant under low shear and low temperature, forming into pieces, drying |
| 12/31/2002 | US6500433 Polypeptide fragments capable of competition with Streptococcus mutans antigen I/II |
| 12/31/2002 | US6500424 Bacterial strain, processed plant extracts, compositions containing same, processes for their preparation and their therapeutic and industrial applications |
| 12/31/2002 | US6500423 Probiotic composition comprising viable escherichia coli strain bu-230-98 atcc deposit no. 20226 (dsm 12799) and a formulation for maintaining viability of said escherichia coli strain |
| 12/31/2002 | US6500409 Oral antigingivitis composition comprising an orally acceptable vehicle of a combination of a noncationic halogenated hydroxydiphenyl ether and an extract of magnolia cortex, the bark of magnolia officinalis such as magnolol |
| 12/31/2002 | CA2227814C Substituted benzylaminopiperidine compounds |
| 12/27/2002 | WO2002103055A1 METHOD OF DETERMINING A CHEMOTHERAPEUTIC REGIMEN BASED ON GLUTATHIONE-S-TRANSFERASE Pi EXPRESSION |
| 12/27/2002 | WO2002103014A2 Antisense oligonucleotides which can inhibit the formation of capillary tubes by endothelial cells |
| 12/27/2002 | WO2002102997A2 Isolated homozygous stem cells differentiated cells derived therefrom and materials and methods for making and using same |
| 12/27/2002 | WO2002102990A2 Fibroblast growth factor and nucleic acid encoding same |
| 12/27/2002 | WO2002102975A2 Dna molecules and recombinant dna molecules for producing humanized monoclonal antibodies to s. mutans |
| 12/27/2002 | WO2002102801A1 Tropane derivatives and their use as monoamine neurotransmitter re-uptake inhibitors |
| 12/27/2002 | WO2002102800A1 5-(2-aminopyrimidin-4-yl) benzisoxazoles as protein kinase inhibitors |
| 12/27/2002 | WO2002102794A2 Polymorphic forms of 1-'4-(5-cyanoindol-3-yl)butyl-4-(2-carbamoylbenzofuran-5-yl)piperazine hydrochloride |
| 12/27/2002 | WO2002102782A2 QUINAZOLINE DERIVATIVES which PROMOTE THE RELEASE OF PARATHYROID_HORMONE |
| 12/27/2002 | WO2002102778A1 Phenylpyridine carbonyl piperazine derivative |
| 12/27/2002 | WO2002102774A1 4-piperazinylindole derivatives with 5-ht6 receptor affinity |
| 12/27/2002 | WO2002102771A1 Tryptase inhibitors |
| 12/27/2002 | WO2002102414A1 Medicinal compositions |
| 12/27/2002 | WO2002102403A1 Mucosal repair by tff dimer peptides |
| 12/27/2002 | WO2002102399A2 Mucosal repair by tff2 peptides |
| 12/27/2002 | WO2002102383A1 Aqueous cilostazol preparation for injection |
| 12/27/2002 | WO2002102377A1 Immune response modifiers for the treatment of periodontal disease |
| 12/27/2002 | WO2002102375A2 Imidazole derivatives for modulating sodium channels |
| 12/27/2002 | WO2002102357A1 A coated nicotine-containing chewing gum, manufacture and use thereof |
| 12/27/2002 | WO2002102315A2 QUINAZOLINE AND PYRIDO[2,3-d]PYRIMIDINE INHIBITORS OF PHOSPHODIESTERASE (PDE) 7 |
| 12/27/2002 | WO2002102314A2 Purine inhibitors of phosphodiesterase (pde) 7 |
| 12/27/2002 | WO2002102313A2 Pyrimidine inhibitors of phosphodiesterase (pde) 7 |
| 12/27/2002 | WO2002102310A2 Proteins associated with cell growth, differentiation, and death |
| 12/27/2002 | WO2002102305A2 Adjuvant composition for mucosal and injection delivered vaccines |
| 12/27/2002 | WO2002102129A2 Process for the preparation of programmed liberation compositions with venlafaxine and the resulting product |
| 12/27/2002 | WO2002087626A9 Pharmaceutical compositions comprising dendritic cells for immunotherapy of autoimmune disease and treatment methods using the same |
| 12/27/2002 | WO2002083696A3 Novel cyclo azaphospha hydrocarbons |
| 12/27/2002 | WO2002076946A3 Fused pyridine derivatives for use as vanilloid receptor antagonists for treating pain. |
| 12/27/2002 | WO2002055087B1 Dihydro-triterpenes in the treatment of viral infections, cardiovascular disease, inflammation, hypersensitivity or pain |
| 12/27/2002 | WO2002018445A8 Co-crystal structure of monoclonal antibody 5c8 and cd154, and use thereof in drug design |
| 12/27/2002 | WO2002012467A3 Drug metabolizing enzymes |
| 12/27/2002 | WO2001081404A3 INDUCIBLE PLASMID VECTOR ENCODING TGF-β AND USES THEREOF |
| 12/27/2002 | WO2001074903A9 Cd20/ige-receptor like molecules and uses thereof |
| 12/27/2002 | WO2001021574A9 Systems and methods for opening obstructed biological conduits |
| 12/27/2002 | CA2782868A1 Polymorphic forms of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl)piperazine hydrochloride |
| 12/27/2002 | CA2782865A1 Polymorphic forms of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl)piperazine hydrochloride |
| 12/27/2002 | CA2782862A1 Polymorphic forms of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl)piperazine hydrochloride |
| 12/27/2002 | CA2782857A1 Polymorphic forms of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl)piperazine hydrochloride |
| 12/27/2002 | CA2782791A1 Polymorphic forms of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl)piperazine hydrochloride |
| 12/27/2002 | CA2782761A1 Polymorphic forms of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl)piperazine hydrochloride |
| 12/27/2002 | CA2782628A1 Polymorphic forms of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl)piperazine hydrochloride |
| 12/27/2002 | CA2782623A1 Polymorphic forms of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl)piperazine hydrochloride |
| 12/27/2002 | CA2782615A1 Polymorphic forms of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl)piperazine hydrochloride |
| 12/27/2002 | CA2782521A1 Polymorphic forms of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl) piperazine hydrochloride |
| 12/27/2002 | CA2782519A1 Polymorphic forms of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl) piperazine hydrochloride |
| 12/27/2002 | CA2782517A1 Polymorphic forms of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl) piperazine hydrochloride |
| 12/27/2002 | CA2782515A1 Polymorphic forms of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl)piperazine hydrochloride |
| 12/27/2002 | CA2782494A1 Polymorphic forms of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl)piperazine hydrochloride |
| 12/27/2002 | CA2456864A1 Adjuvant composition for mucosal and injection delivered vaccines |